3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Pancreatic Neoplasms
3
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Synovitis, Pigmented Villonodular
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphoma, T-Cell, Peripheral
1
Head and Neck Neoplasms
1
Glioma
1
Giant Cell Tumor of Tendon Sheath
1
Carcinoma, Hepatocellular
1
Advanced Pancreatic Cancer
1
Advanced Malignancies
1
Interventions
Temozolomide
47
Bevacizumab
41
Radiotherapy
17
Magnetic Resonance Spectroscopy
14
Irinotecan
11
Nivolumab
8
Everolimus
7
Radiation
6
poly ICLC
5
X-Rays
5
Phantoms, Imaging
5
Carboplatin
5
pembrolizumab
4
fluorodopa F 18
4
Specimen Handling
4
Nuclear Medicine Department, Hospital
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
Erlotinib Hydrochloride
4
Carmustine
4
ribociclib
3
palbociclib
3
ivosidenib
3
antineoplaston A10
3
Vorinostat
3
Radiotherapy, Intensity-Modulated
3
Radiosurgery
3
Modafinil
3
Lomustine
3
Biopsy
3
veliparib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Glioma
×
cabiralizumab
×
Clear all
NCT02526017
2022-03-09
FPA008-003
Five Prime Therapeutics, Inc.
Phase 1
Completed
313 enrolled
30 charts